# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment ch...
Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypo...
TD Cowen analyst Yaron Werber upgrades Ascendis Pharma (NASDAQ:ASND) from Hold to Buy and raises the price target from $156 ...
The data showed that patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in w...
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated...
Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...